Duane Boise stated "At the center of the MMJ cannabis pharmaceutical litigation sits DEA Thomas Prevoznik, an unearthed official with no medical or scientific expertise, who wields unchecked power to deny therapies under the guise of public safety."
MMJ BioPharma Cultivation: A Case Study in DEA Sabotage
Read MoreData from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with genital psoriasis achieved site-specific clear or almost clear skin at Week 16
Icotrokinra continues to demonstrate a standout combination of significant skin clearance (IGA 0/1) and a favorable safety profile in a once daily pill
PN-881, a first-in-class oral peptide targeting the IL-17 pathway, potently and selectively binds IL-17A and -17F, blocking the three dimeric forms of the cytokine
Read More
OTUS Launches in the U.S. as a Smart Vision Training Solution for Modern Vision Therapy Centers.
Built for professionals, OTUS enables more efficient and precise accommodative training through AI-driven automation and real-time data management.
Read More
Should one unelected bureaucrat, Deputy Assistant Administrator Thomas Prevoznik, possess the unchecked authority to obstruct FDA authorized drug development and derail critical scientific breakthroughs in the United States just because they are utilizing extract from the marijuana plant? The time for excuses is over. The time for action is now.
Read MoreCompany's Canalevia®-CA1 (crofelemer delayed-release tablets) prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and only treatment for CID in dogs to receive any type of approval from FDA
Read MoreAs lead candidate mipletamig continues to outperform efficacy and safety benchmarks in AML trials, APVO711 exemplifies emerging innovation from Aptevo's proprietary ADAPTIR® platform
In preclinical studies, APVO711 demonstrates dual anti-cancer functionality with broad solid tumor potential and developability
Read MoreWith valuations confirmed by the board, MIRA advances strategic acquisition targeting obesity and nicotine dependence, which includes a $5 million contribution in cash or assets from SKNY to be transferred at closing.
Read More
New IT Sector Report Evaluates 300+ Vendors Across 40 Categories, Revealing 2025's Top-Rated Solutions in Women's Health Technology
Read More
Sportstech Announced Strong Results, with April 2025 revenue growth at 36% YOY
Current FX rates indicate that the LTM figures would be approximately $54M in Revenue and $5M in EBITDA through April 2025
Strong Business Momentum, Revenue and Positive EBITDA Underscore Target's Operational Strength and Logic of Acquisition in advance of Closing
Read More
DEA's Diversion Control Division leadership implicated in the obstruction of MMJ 's DEA registration and delays in cannabis-based pharmaceutical research are Thomas W. Prevoznik, Matthew Strait and DEA Administrative Law Judges (ALJs) all who under the agency's control, raising serious concerns about due process, impartiality, and accountability.
Read More
N-trans-caffeoyltyramine (NCT) is a natural product compound attracting considerable interest from researchers and drug developers for its potential role in healthy liver fat metabolism, gut barrier function, and mitochondrial activity.
eXoZymes used its AI-driven development platform to progress from idea to purpose-built subsidiary in less than 3 months and at a fraction of normal SynBio R&D cost.
NCTx is scaling up an exozyme biosolution to overcome a longstanding bottleneck in sourcing the NCT compound from nature, where it occurs only in trace amounts.
Interesting pre-clinical data point towards Non-Alcoholic Fatty Liver Disease (NAFLD) that affects more than 30% of the global population.
Only NCTx can make both the natural product NCT, and a range of very interesting new-to-nature analog versions, expanding the pharma potential.
NCT is the first of more "powered by eXoZymes" natural product nutraceuticals, that also have the potential to become pharmaceuticals.
Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1st
Conference call to be held June 2nd at 8AM EDT to discuss rusfertide data presented at ASCO
Full dataset from Phase 3 ICONIC-LEAD trial with icotrokinra in patients with moderate-to-severe plaque psoriasis (PsO) presented at the 2025 AAD Meeting in March; data from adolescent subset presented at World Congress of Pediatric Dermatology in April
Positive top line results from icotrokinra Phase 2b ANTHEM trial in moderately to severely active ulcerative colitis (UC) announced in March, data to be presented at medical conference later in 2025
Cash, cash equivalents and marketable securities of $697.9 million as of March 31, 2025, anticipated to provide cash runway through at least end of 2028
Read More
Addison Care delivers the industry's most comprehensive AI-enabled chronic care platform - offering vitals monitoring, automated wellness checks, caregiver support, and integrated TeleCare services - now accessible to thousands of clinics through Athenahealth's nationwide EHR ecosystem.
Read More
Nerva, the world's leading digital therapeutic for Irritable Bowel Syndrome (IBS), announced today that it has acquired key assets of Mahana Therapeutics, a pioneer in digital therapies for chronic conditions, including IBS.
Read MorePreclinical data supports the advancement of oral Ketamir-2 as a safe, next-generation alternative to ketamine, with ongoing momentum in Phase I clinical trial enrollment
Read More
With six newly established, identical BSL-2 laboratories now operational, biologics CDMO Northway Biotech can conduct VCS programs for up to six clients simultaneously, significantly alleviating current market bottlenecks
Read More
Message to President Trump's Appointee: Terrance Cole Must Act on Cannabis Scientific Reform.
"Mr. Cole has a historic opportunity to lead with integrity, science, and constitutional fidelity," said Boise. "He must put an end to this unlawful administrative hearing, root out DEA institutional marijuana bias, and restore lawful science-based regulatory practices."
Read More
